#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	17608	16S	1529	1529	100.0	16S.l6.c17.ctg.1	2581	840.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1668	1668	C	1117	C,T	1115,2	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29338	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4103	892.6	0	.	n	.	0	T695C	SNP	695	695	T	1275	1275	C	1081	C,G,T,A	1075,3,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29338	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4103	892.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	1917	1917	A	1174	A	1174	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29338	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4103	892.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2551	2551	C	1015	C,T,A	1012,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29338	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4103	892.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2625	2625	A	989	A,G	988,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29338	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4103	892.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	3177	3177	C	1030	C,T	1029,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2542	folP	852	852	100.0	folP.l15.c4.ctg.1	2066	153.3	1	SNP	p	R228S	1	.	.	682	684	AGC	1232	1234	AGC	249;251;251	A,C;G;C,A	248,1;251;250,1	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5660	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3783	186.3	1	SNP	p	S91F	0	.	.	271	273	TCC	748	750	TCC	226;228;230	T,G;C,G;C	225,1;227,1;230	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5660	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3783	186.3	1	SNP	p	D95G	0	.	.	283	285	GAC	760	762	GAC	230;227;227	G;A;C	230;227;227	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5660	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3783	186.3	1	SNP	p	D95N	0	.	.	283	285	GAC	760	762	GAC	230;227;227	G;A;C	230;227;227	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	2108	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1987	132.6	0	.	p	.	0	A39T	NONSYN	115	117	GCC	750	752	ACC	208;207;208	A;C;C,A	208;207;207,1	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	2108	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1987	132.6	0	.	p	.	0	R44H	NONSYN	130	132	CGC	765	767	CAC	194;193;195	C;A;C	194;193;195	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	2108	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1987	132.6	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	948	950	CAC	289;290;292	C;A;C	289;290;292	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	2108	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1987	132.6	1	SNP	p	G45D	0	.	.	133	135	GGC	768	770	GGC	197;199;199	G;G,C;C,G	197;198,1;198,1	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1298	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1585	102.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5624	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3378	207.4	1	SNP	p	D86N	0	.	.	256	258	GAC	783	785	GAC	275;278;279	G;A,T;C,T	275;277,1;278,1	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5624	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3378	207.4	1	SNP	p	S87I	0	.	.	259	261	AGT	786	788	AGT	279;279;275	A;G,T;T,A	279;278,1;274,1	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5624	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3378	207.4	1	SNP	p	S87W	0	.	.	259	261	AGT	786	788	AGT	279;279;275	A;G,T;T,A	279;278,1;274,1	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5624	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3378	207.4	1	SNP	p	S87R	0	.	.	259	261	AGT	786	788	AGT	279;279;275	A;G,T;T,A	279;278,1;274,1	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5624	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3378	207.4	1	SNP	p	S88P	0	.	.	262	264	TCC	789	791	TCC	274;273;274	T,C;C;C	273,1;273;274	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4822	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3136	191.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1837	1839	GGC	269;271;268	G;G;C,G	269;271;267,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4678	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2761	210.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1458	1460	GCA	274;277;276	G,A;C;A	273,1;277;276	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4678	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2761	210.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1461	1463	ATC	272;270;271	A;T;C,A	272;270;270,1	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4678	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2761	210.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1473	1475	GTG	280;284;284	G;T;G,T	280;284;282,2	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4678	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2761	210.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1473	1475	GTG	280;284;284	G;T;G,T	280;284;282,2	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4678	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2761	210.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1977	1979	ACC	246;249;247	A;C;C	246;249;247	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4678	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2761	210.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2031	2033	GCG	258;258;252	G;C,T,A;G	258;256,1,1;252	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4678	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2761	210.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2031	2033	GCG	258;258;252	G;C,T,A;G	258;256,1,1;252	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4678	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2761	210.9	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2154	2156	GGC	257;256;257	G;G;C	257;256;257	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4678	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2761	210.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2163	2165	GGC	257;253;255	G,A;G;C	255,2;253;255	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4678	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2761	210.9	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2181	2183	CCG	257;257;252	C;C;GCCC,GCC	257;257;244,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	6404	ponA	2397	2397	99.96	ponA.l15.c17.ctg.1	3520	227.1	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1840	1842	CTG	249;251;251	C;T;G	249;251;251	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2860	porA	1146	1146	99.83	porA.l6.c17.ctg.1	2369	150.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	756	756	C	220	C	220	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3044	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1928	195.4	0	.	p	.	0	E48G	NONSYN	142	144	GAA	601	603	GGA	295;290;288	G;G;A	295;290;288	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3044	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1928	195.4	0	.	p	.	0	G129S	NONSYN	385	387	GGC	844	846	AGC	209;204;202	A;G,A;C	209;203,1;202	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3044	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1928	195.4	0	.	p	.	0	F135L	NONSYN	403	405	TTT	862	864	CTT	224;225;227	C;T;T,G,C	224;225;225,1,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3044	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1928	195.4	0	.	p	.	0	R143G	NONSYN	427	429	AGA	886	888	GGA	248;249;249	G;G,C;A	248;247,2;249	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3044	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1928	195.4	0	.	p	.	0	D171G	NONSYN	511	513	GAT	970	972	GGT	275;277;275	G;G;T	275;277;275	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3044	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1928	195.4	0	.	p	.	0	G189S	NONSYN	565	567	GGC	1024	1026	AGC	278;282;283	A;G;C	278;282;283	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3044	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1928	195.4	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1090	1090	T	257	T	257	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3044	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1928	195.4	1	SNP	p	G120K	0	.	.	358	360	GGT	817	819	GGT	231;232;234	G,A;G;T,C	230,1;232;233,1	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3044	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1928	195.4	1	SNP	p	A121N	0	.	.	361	363	GCC	820	822	GCC	231;230;232	G,C;C;C,A	230,1;230;231,1	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3044	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1928	195.4	1	SNP	p	A121D	0	.	.	361	363	GCC	820	822	GCC	231;230;232	G,C;C;C,A	230,1;230;231,1	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11102	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	5367	258.3	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2213	2215	AAT	286;286;286	A;A;T	286;286;286	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1626	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1493	135.7	1	SNP	p	V57M	1	.	.	169	171	ATG	726	728	ATG	301;303;302	A;T;G	300;303;302	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
